Weiguo Su, Hutchmed CEO

FDA hits Hutchmed, Jun­shi drugs with CRLs — fur­ther clar­i­fy­ing its stance on Chi­na-on­ly da­ta

The FDA is firm­ly shut­ting the door to Chi­na-on­ly da­ta when it comes to ap­prov­ing new can­cer drugs — with some ex­cep­tions.

Just over a month …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.